Staff Reports
Ambassador Jeffrey Gerrish recently wrote a plain‑spoken op‑ed urging the U.S. to hit back at foreign drug price freeloaders. He wants the Office of the U.S. Trade Representative to open a formal Section 301 probe into how other wealthy governments cap drug prices — and to use trade tools, including tariffs, to force fairer payments for American innovation. It’s a blunt, market‑first plan to blunt China’s growing edge in drug development and protect American biotech jobs.
Gerrish’s Call: Use Section 301 to Stop Free‑Riding
Gerrish says it’s time to stop letting other rich countries get a free ride on U.S. innovation. He urges a Section 301 investigation so the U.S. can legally press those nations to pay more for innovative medicines. That’s a job for USTR Jamieson Greer and the Trump administration’s trade team. The idea is simple: if foreign price caps drain revenue from U.S. drugmakers, those companies won’t have the cash to fund the next big breakthrough. Trade enforcement would be a direct way to change the math.
The China Biotech Challenge
Why does this matter? China is sprinting in clinical trials and drug development. Many independent counts show China’s registered trial activity has climbed fast, and in some measures it now rivals or exceeds U.S. activity. Gerrish warns that if America keeps bleeding revenue to cheaper foreign markets, we risk depending on China for the next big cure. That would be a strategic mistake — giving another nation leverage over life‑saving therapies without a single shot fired. Sounds dramatic? Yes. But it’s also common sense.
Enforcement, Not Price Controls
Gerrish is adamant that copying foreign price caps here would be self‑inflicted harm. When you cap prices at home, you remove the very incentives that fund risky R&D. That would hand China a built‑in advantage. Trade penalties and deal‑making, not domestic price caps, are his prescription. He points to the U.S.‑U.K. pharmaceutical understanding as an example of how leverage can be used to get better outcomes. In short: don’t tax innovation into decline — make other countries pay their share instead.
A Conservative Roadmap: Enforce, Invest, and Outcompete
If conservatives want a real answer to China’s biotech push, Gerrish’s plan is a tidy start. First, USTR should open a Section 301 inquiry and lay out clear demands. Second, the administration should use the leverage of trade talks to get allies to shoulder fairer prices. Third, Congress and the White House need targeted investments to expand U.S. manufacturing and clinical capacity so breakthroughs are made and produced on American soil. That mix of enforcement and investment protects patients, protects inventors, and keeps American biotech competitive. If Washington acts with spine instead of slogans, we can beat China at its own game without surrendering our market or our future.
